27896785|t|Prescription Patterns of Medications for Alzheimer's Disease in Japan from 2010 to 2015: A Descriptive Pharmacy Claims Database Study
27896785|a|Although four kinds of Alzheimer's disease (AD) drugs are available at present there was only one drug until 2011 in Japan. This study aimed to elucidate prescription trends of these medications for AD in Japanese outpatients before and after the new drug releases in 2011. This descriptive study of pharmacy claims databases analyzed outpatient prescription data from community pharmacies across Japan. The study patients were 20 years or older and first administered medications for AD (donepezil, memantine, rivastigmine, or galantamine) between January 2010 and September 2014. They were grouped on the basis of the year of their initial medications for AD administration into the 2010-2011 and 2012-2014 groups (1 and 2, respectively) and their characteristics and AD treatments were summarized by group. The subanalyses used a multivariable logistic regression model to examine the relationship between patient characteristics and discontinuation or change to combination therapy within a year. A total of 103,592 patients (group 1 and 2, 28,581 and 75,011, respectively) were prescribed medications for AD during the study period. The group 1 and 2 mean ± standard deviation (SD) ages were 79.6 ± 7.4 and 80.9 ± 7.3 years while female patients constituted 64.0% and 64.5%, respectively. Furthermore, in groups 1 and 2 patients, 99.0% and 94.3% received a medication for AD monotherapy, 92.3% and 59.6% were prescribed donepezil, and 40.5% and 41.5% discontinued treatment within a year, respectively. The subanalyses suggest that being at least 85 years old strongly correlated with treatment discontinuation and change to combination therapy within a year. Although the prescription proportions of the various medications for AD have changed since 2011, no apparent changes occurred in the patient characteristics of those who initiated AD treatment between 2010-2011 and 2012-2014.
27896785	0	12	Prescription	T170	C1521941
27896785	13	21	Patterns	T082	C0449774
27896785	25	36	Medications	T058	C2081612
27896785	41	60	Alzheimer's Disease	T047	C0002395
27896785	64	69	Japan	T083	C0022341
27896785	91	102	Descriptive	T170	C0678257
27896785	103	111	Pharmacy	T091	C0031336
27896785	119	127	Database	T170	C0242356
27896785	128	133	Study	T062	C2603343
27896785	157	176	Alzheimer's disease	T047	C0002395
27896785	178	180	AD	T047	C0002395
27896785	182	187	drugs	T121	C0013227
27896785	192	201	available	T169	C0470187
27896785	205	212	present	T079	C0521116
27896785	232	236	drug	T121	C0013227
27896785	251	256	Japan	T083	C0022341
27896785	263	268	study	T062	C2603343
27896785	269	274	aimed	T078	C1947946
27896785	278	287	elucidate	T052	C2986669
27896785	288	300	prescription	T170	C1521941
27896785	301	307	trends	T079	C0040833
27896785	317	328	medications	T058	C2081612
27896785	333	335	AD	T047	C0002395
27896785	339	347	Japanese	T098	C1556094
27896785	348	359	outpatients	T101	C0029921
27896785	360	366	before	T079	C0332152
27896785	371	376	after	T079	C0687676
27896785	385	389	drug	T121	C0013227
27896785	390	398	releases	T170	C0282424
27896785	413	424	descriptive	T170	C0678257
27896785	425	430	study	T062	C2603343
27896785	434	442	pharmacy	T091	C0031336
27896785	450	459	databases	T170	C0242356
27896785	460	468	analyzed	T062	C0936012
27896785	469	479	outpatient	T101	C0029921
27896785	480	497	prescription data	T170	C1521941
27896785	503	523	community pharmacies	T093	C0009478
27896785	531	536	Japan	T083	C0022341
27896785	542	547	study	T062	C2603343
27896785	548	556	patients	T101	C0030705
27896785	565	570	years	T079	C0439234
27896785	590	602	administered	T061	C1533734
27896785	603	614	medications	T058	C2081612
27896785	619	621	AD	T047	C0002395
27896785	623	632	donepezil	T109,T121	C0527316
27896785	634	643	memantine	T109,T121	C0025242
27896785	645	657	rivastigmine	T109,T121	C0649350
27896785	662	673	galantamine	T109,T121	C0016967
27896785	726	733	grouped	T082	C0439745
27896785	741	746	basis	T169	C1527178
27896785	754	758	year	T079	C0439234
27896785	768	775	initial	T079	C0205265
27896785	776	787	medications	T058	C2081612
27896785	792	794	AD	T047	C0002395
27896785	795	809	administration	T061	C1533734
27896785	843	849	groups	T078	C0441833
27896785	884	899	characteristics	T080	C1521970
27896785	904	906	AD	T047	C0002395
27896785	907	917	treatments	T061	C0087111
27896785	923	936	summarized by	T170	C1553398
27896785	937	942	group	T078	C0441833
27896785	948	959	subanalyses	T062	C0936012
27896785	967	1006	multivariable logistic regression model	UnknownType	C0681925
27896785	1010	1017	examine	T033	C0332128
27896785	1022	1034	relationship	T080	C0439849
27896785	1043	1050	patient	T101	C0030705
27896785	1051	1066	characteristics	T080	C1521970
27896785	1071	1086	discontinuation	T061	C4288399
27896785	1090	1096	change	T169	C0392747
27896785	1100	1119	combination therapy	T061	C0013218
27896785	1129	1133	year	T079	C0439234
27896785	1154	1162	patients	T101	C0030705
27896785	1164	1169	group	T078	C0441833
27896785	1217	1227	prescribed	T058	C0278329
27896785	1228	1239	medications	T058	C2081612
27896785	1244	1246	AD	T047	C0002395
27896785	1258	1263	study	T062	C2603343
27896785	1276	1281	group	T078	C0441833
27896785	1290	1294	mean	T081	C0444504
27896785	1297	1315	standard deviation	T081	C0871420
27896785	1317	1319	SD	T081	C0871420
27896785	1357	1362	years	T079	C0439234
27896785	1369	1375	female	T032	C0086287
27896785	1376	1384	patients	T101	C0030705
27896785	1444	1450	groups	T078	C0441833
27896785	1459	1467	patients	T101	C0030705
27896785	1496	1506	medication	T058	C2081612
27896785	1511	1513	AD	T047	C0002395
27896785	1514	1525	monotherapy	T061	C0520016
27896785	1548	1558	prescribed	T058	C0278329
27896785	1559	1568	donepezil	T109,T121	C0527316
27896785	1590	1612	discontinued treatment	T061	C4288399
27896785	1622	1626	year	T079	C0439234
27896785	1646	1657	subanalyses	T062	C0936012
27896785	1658	1665	suggest	T078	C1705535
27896785	1689	1694	years	T079	C0439234
27896785	1699	1707	strongly	T080	C0442821
27896785	1708	1718	correlated	T080	C1707520
27896785	1724	1749	treatment discontinuation	T061	C4288399
27896785	1754	1760	change	T169	C0392747
27896785	1764	1783	combination therapy	T061	C0013218
27896785	1793	1797	year	T079	C0439234
27896785	1812	1824	prescription	T170	C1521941
27896785	1825	1836	proportions	T081	C1709707
27896785	1852	1863	medications	T058	C2081612
27896785	1868	1870	AD	T047	C0002395
27896785	1876	1883	changed	T169	C0392747
27896785	1899	1907	apparent	T078	C0750489
27896785	1908	1915	changes	T169	C0392747
27896785	1932	1939	patient	T101	C0030705
27896785	1940	1955	characteristics	T080	C1521970
27896785	1969	1978	initiated	T169	C1704686
27896785	1979	1981	AD	T047	C0002395
27896785	1982	1991	treatment	T061	C0087111